Concepedia

Greg Andrew Durm

GA

Statistics

Publications

15

Citations

656

H-Index

13

Active since

2018

Affiliations

Indiana University – Purdue University Indianapolis(Current)

Indiana University Health

Memorial Sloan Kettering Cancer Center

The University of Texas MD Anderson Cancer Center

Sarah Cannon

Greg Andrew Durm is an author at Indiana University – Purdue University Indianapolis specializing in oncology, medicine, and chemotherapy.

ORCID

Publications per year

2018–2025

15

Publications

15

A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non–small cell lung cancer: Hoosier Cancer Research Network LUN 14‐179

Greg Andrew Durm, Salma K. Jabbour, Sandra K. Althouse et al. · Cancer · 2020 · 164 citations · Full text

, , +17

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025

A. Dimitrios Colevas, Anthony J. Cmelak, David G. Pfister et al. · Journal of the National Comprehensive Cancer Network · 2025 · 133 citations

, , +17

Phase II trial of concurrent chemoradiation with consolidation pembrolizumab in patients with unresectable stage III non-small cell lung cancer: Hoosier Cancer Research Network LUN 14-179.

Greg Andrew Durm, Sandra K. Althouse, Ahad A. Sadiq et al. · Journal of Clinical Oncology · 2018 · 52 citations

, , +16

Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours

Ramaswamy Govindan, Marwan Fakih, Timothy Price et al. · Annals of Oncology · 2019 · 41 citations · Full text

, , +12

CX-072 (pacmilimab), a Probody<b> <sup>®</sup> </b> PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Aung Naing, Fiona Thistlethwaite, Elisabeth G.E. de Vries et al. · Journal for ImmunoTherapy of Cancer · 2021 · 39 citations · Full text

, , +17

1–5 of 15